Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
|
| Abstract |
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and the most frequent invasive infection due to methicillin-resistant S. aureus (MRSA). Treatment is challenging, particularly for MRSA, because of limited treatment options. Telavancin is a bactericidal lipoglycopeptide antibiotic that is active against a range of clinically relevant gram-positive pathogens including MRSA. In experimental animal models of sepsis telavancin was shown to be more effective than vancomycin. In clinically evaluable patients enrolled in a pilot study of uncomplicated SAB, cure rates were 88% for telavancin and 89% for standard therapy. Among patients with infection due to only gram-positive pathogens enrolled in the 2 phase 3 studies of telavancin for treatment of hospital-acquired pneumonia, cure rates for those with bacteremic S. aureus pneumonia were 41% (9/22, telavancin) and 40% (10/25, vancomycin) with identical mortality rates. These data support further evaluation of telavancin in larger, prospective studies of SAB.
|
|---|---|
| Authors | G Ralph Corey, Ethan Rubinstein, Martin E Stryjewski, Matteo Bassetti, Steven L Barriere |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 60 Issue 5 Pg. 787-96 (Mar 01 2015) ISSN: 1537-6591 [Electronic] United States |
| PMID | 25472944 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review) |
| Copyright | © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!